PubRank

P J Lefèbvre

Author PubWeight™ 52.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998 1.76
2 The intrathymic expression of insulin-related genes: implications for pathophysiology and prevention of Type 1 diabetes. Diabetes Metab Rev 1998 1.58
3 No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000 1.25
4 Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. J Clin Endocrinol Metab 1991 1.15
5 Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996 1.12
6 Severe/extreme obesity: a medical disease requiring a surgical treatment? Acta Clin Belg 1999 1.06
7 The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level. J Clin Endocrinol Metab 1996 1.02
8 Factors controlling gastric-glucagon release. J Clin Invest 1977 1.02
9 A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 1983 0.98
10 Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil Steril 1986 0.96
11 Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia 1986 0.93
12 Metabolic control may influence the increased superoxide generation in diabetic serum. Diabet Med 1991 0.92
13 How to measure insulin clearance. Diabetes Metab Rev 1994 0.92
14 Insulin action in man. Diabetes Metab 1996 0.89
15 Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 1993 0.89
16 Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Diabetologia 1996 0.88
17 Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Diabetes Care 1984 0.87
18 The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 2004 0.86
19 Effect of dog jejunum "glucagon-like immunoreactive material" on adipose tissue metabolism. Horm Metab Res 1969 0.86
20 Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type 1 diabetes. J Clin Endocrinol Metab 1988 0.86
21 Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab 1995 0.85
22 Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med 1995 0.84
23 Metabolic adaptations in post-exercise recovery. Clin Physiol 1982 0.84
24 A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia 1983 0.84
25 Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Saf 1995 0.83
26 Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991 0.83
27 Oral antidiabetic agents. A guide to selection. Drugs 1998 0.82
28 Postgastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995 0.82
29 [Reactive hypoglycaemia, a mysterious, insidious but non dangerous critical phenomenon]. Rev Med Liege 2004 0.82
30 Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord 1994 0.81
31 How to measure insulin action in vivo. Diabetes Metab Rev 1994 0.81
32 Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. Diabet Med 2003 0.80
33 From plant physiology to human metabolic investigations. Diabetologia 1985 0.79
34 Statement on postprandial hypoglycemia. Diabetes Care 1988 0.79
35 Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 1999 0.79
36 Primary role of glucagon release in the effect of beta-endorphin on glucose homeostasis in normal man. Acta Endocrinol (Copenh) 1987 0.79
37 Opioid peptides and metabolic regulation. Diabetologia 1988 0.79
38 Endogenous substrate oxidation during exercise and variations in breath 13CO2/12CO2. J Appl Physiol (1985) 1993 0.79
39 Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Int J Obes Relat Metab Disord 1995 0.79
40 Variability of albumin excretion in insulin-dependent diabetics. Diabet Med 1987 0.78
41 European Dimension of Diabetes Research. Diabetologia 1996 0.78
42 [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?]. Rev Med Liege 2003 0.78
43 The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol (Copenh) 1987 0.78
44 Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia 1989 0.78
45 Intact cross-talk between insulin secretion and insulin action after postgastroplasty recovery of ideal body weight in severely obese patients. Int J Obes Relat Metab Disord 2004 0.77
46 Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement. Diabetes Metab 1996 0.77
47 Insulin sensitivity in anorexia nervosa: a mirror image of obesity? Diabetes Metab Rev 1988 0.77
48 Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes 1987 0.77
49 Pulsatile glucagon has greater hyperglycaemic, lipolytic and ketogenic effects than continuous hormone delivery in man: effect of age. Diabetologia 1990 0.77
50 Assessment of postprandial hepatic glycogen synthesis from uridine diphosphoglucose kinetics in obese and lean non-diabetic subjects. Int J Obes Relat Metab Disord 2000 0.77
51 Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract 1989 0.76
52 Decreased or increased insulin metabolism after glipizide in type II diabetes. Diabetes Care 1988 0.76
53 Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1988 0.76
54 Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000 0.76
55 Non-alcoholic steatohepatitis. Lancet 1999 0.76
56 Utilization of oral sucrose load during exercise in humans. Effect of the alpha-glucosidase inhibitor acarbose. Diabetes 1986 0.76
57 Acarbose in reactive hypoglycemia: a double-blind study. Int J Clin Pharmacol Ther Toxicol 1984 0.76
58 Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. Fertil Steril 1993 0.76
59 Glucose turnover in humans in the basal state and after intravenous glucose: a comparison of two models. Am J Physiol 1997 0.76
60 Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg 1993 0.76
61 Pathogenic tracks in fatigue syndromes. Acta Clin Belg 1994 0.75
62 Exogenous glucose oxidation during exercise in relation to the power output. Int J Sports Med 1995 0.75
63 Influence of the A-->G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects. Int J Obes Relat Metab Disord 1998 0.75
64 [Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes]. Rev Med Liege 1999 0.75
65 Use of 13C substrates for metabolic studies in exercise: methodological considerations. J Appl Physiol (1985) 1991 0.75
66 [Etiopathogenesis, physiopathology and general principles of therapy of type II diabetes]. Rev Med Liege 1988 0.75
67 [Rapid determination by immunoassay of glycosylated hemoglobin in capillary blood compared to an affinity method for boronate and ion capturing on venous blood]. Ann Biol Clin (Paris) 1997 0.75
68 [Metabolic and hormonal response to a standardized breakfast in type 2 diabetes. Effect of glipizide]. Rev Med Liege 1983 0.75
69 Relationships between metabolic clearance rate of insulin and body mass index in a female population ranging from anorexia nervosa to severe obesity. Int J Obes Relat Metab Disord 1994 0.75
70 [Postprandial hyperglycemia. I. Physiopathology, clinical consequences and dietary management]. Rev Med Liege 2002 0.75
71 [Diabetes mellitus: epilogue]. Rev Med Liege 2005 0.75
72 [Syndrome of reactive hypoglycemia. Myth or reality]. Journ Annu Diabetol Hotel Dieu 1983 0.75
73 Blood collection while using a continuous glucose analyzer without insertion of an additional venous catheter. Diabetologia 1983 0.75
74 Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII. Diabetes Care 1988 0.75
75 Glucose utilization during exercise in normal and diabetic subjects. The role of insulin. Diabetes 1981 0.75
76 [Clinical case of the month. Prolonged spontaneous remission of a typical type 1 diabetes]. Rev Med Liege 1995 0.75
77 Effects of metformin in obese patients with impaired glucose tolerance. Diabetes Metab Rev 1995 0.75
78 [Obesity and women: esthetic preoccupation or medical problem?]. Rev Med Liege 1999 0.75
79 [Gestational diabetes: physiopathology and prognostic significance for the mother]. Rev Med Liege 1999 0.75
80 [How I investigate the new criteria for the diagnosis of diabetes mellitus]. Rev Med Liege 1997 0.75
81 Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade. Eur J Appl Physiol Occup Physiol 1994 0.75
82 [Type 2 insulin-dependent diabetes: patient characteristics and effects of insulin therapy]. Rev Med Liege 1994 0.75
83 [Guidelines for the treatment of arterial hypertension in diabetic patients]. Rev Med Liege 2000 0.75
84 [Microalbuminuria and early detection of diabetic nephropathy]. Rev Med Liege 1986 0.75
85 Effect of phosphate omission on arginine-induced insulin and glucagon release by the isolated perfused rat pancreas. FEBS Lett 1977 0.75
86 [GLycemic control in the diabetic patient. Recommendations after the DCCT and UKPDI studies]. Rev Med Liege 2000 0.75
87 [Unstable diabetes. Definition, causes and consequences]. Journ Annu Diabetol Hotel Dieu 1995 0.75
88 [The unstable diabetic patient: from physiopathology to treatment]. Rev Med Liege 1995 0.75
89 Importance of research training in internal medicine. Acta Clin Belg 1987 0.75
90 [Clinical case of the month. Apropos of a case of ectopic ACTH secretion]. Rev Med Liege 1995 0.75
91 Treatment with insulin infusion pumps and ketoacidotic episodes: from physiology to troubleshooting. Diabetes Metab Rev 1995 0.75
92 [Lessons from the "United Kingdom Prospective Diabetes Study"]. Rev Med Liege 1998 0.75
93 Neuroendocrine-immunology: from systemic interactions to the immune tolerance of self neuroendocrine functions. Acta Clin Belg 1991 0.75
94 [From leptin, a signal from the adipocyte to the brain, to the neurobiology of obesity]. Rev Med Liege 1997 0.75
95 Statement on post-prandial or reactive hypoglycaemia. Diabet Med 1988 0.75
96 [Energy expenditure in man]. Rev Med Liege 1997 0.75
97 Renal control of cephalic and intestinal removal of glucagon in the anesthetized dog. Horm Metab Res 1984 0.75
98 Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Int J Obes Relat Metab Disord 1995 0.75
99 [Pharma clinics. How I treat...a diabetic patient with severe obesity]. Rev Med Liege 1998 0.75
100 [Development and use of a telemedicine system for medical surveillance of diabetic patients]. Journ Annu Diabetol Hotel Dieu 2000 0.75
101 [How I investigate...the insulin resistance syndrome using biological markers]. Rev Med Liege 1997 0.75
102 Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics. Int J Clin Pharmacol Ther Toxicol 1987 0.75
103 U-100 insulin gives some protection against metabolic deterioration due to CSII interruption. Diabetes Care 1988 0.75
104 [The treatment of diabetic ketoacidosis in 1989]. Rev Med Liege 1989 0.75
105 [Importance of the artificial pancreas in the therapeutic approach to insulin-dependent diabetes and in the diagnosis of organic hypoglycemia]. Rev Med Liege 1982 0.75
106 Stimulation of gastric-glucagon release by prostaglandin E1. Prostaglandins Med 1978 0.75
107 [ Change of insulin U40 to insulin U100: comparison of blood insulin and blood sugar in the diabetic patient]. Rev Med Liege 1991 0.75
108 [Viral implications in the etiopathogenesis of type 1 diabetes: current update]. Rev Med Liege 1998 0.75
109 [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients]. Rev Med Liege 2005 0.75
110 Scopion venom-induced release of noradrenalin does not modify glucagon-output from the isolated perfused dog stomach. Horm Metab Res 1978 0.75
111 [Opioid peptides and glucose metabolism]. Rev Med Liege 1987 0.75
112 [How I investigate... a patient newly diagnosed with/or at risk of diabetes type 1]. Rev Med Liege 1997 0.75
113 [Clinical case of the month. Galloping nephropathy in a patient with type 2 diabetes]. Rev Med Liege 1998 0.75
114 Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 0.75
115 [Transition from insulin U-40 to insulin U-100: the Belgian experience]. Diabete Metab 1993 0.75
116 Plasma leptin levels, insulin secretion, clearance and action on glucose metabolism in anorexia nervosa. Eat Weight Disord 1997 0.75
117 Thymic neuroendocrine self peptides and T cell selection. Adv Exp Med Biol 1994 0.75
118 [How I treat ... an individual with severe obesity and metabolic abnormalities with gastroplasty]. Rev Med Liege 1999 0.75
119 [Pharmaco-economics of type 2 diabetes]. Rev Med Liege 1998 0.75
120 Changes in breath 13CO2/12CO2 during exercise of different intensities. J Appl Physiol (1985) 1996 0.75
121 [Non-insulin-dependent diabetes in young subjects]. Rev Med Liege 1989 0.75
122 Metabolic availability of carbohydrates ingested during, before, or after muscular exercise. Diabetes Metab Rev 1986 0.75
123 Therapy for obesity--today and tomorrow. Baillieres Clin Endocrinol Metab 1994 0.75
124 [The adrenergic beta-3 receptor: a role in the genetic predisposition to obesity and diabetes?]. Rev Med Liege 1997 0.75
125 [Thiazolidinediones]. Journ Annu Diabetol Hotel Dieu 1999 0.75
126 [Brain, a gluco-dependent organ: toxic effects of hypoglycaemia and hyperglycaemia]. Rev Med Liege 2008 0.75